Marathon Asset Management 13F: Cuts TMO Stake by $10M
Key Points
- Marathon Asset Management now holds 60,648 shares of Thermo Fisher, down from 76,168 shares, reflecting a 20.4% decrease in its position.
- The fund's reported value for its entire portfolio is about $1.26 billion, with Thermo Fisher representing 3.25% of that total.
- As of October 27, 2026, Thermo Fisher's stock was recently trading around $673.82, which is about 1.6% below its closing price of $684.89 on October 26, 2026.
Get Thermo Fisher Scientific text alerts
We text you when insiders, Congress, analysts or big funds move on $TMO.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Thermo Fisher Scientific Inc. alert may contain errors. Disclosures
On October 26, 2026, Marathon Asset Management reduced its stake in Thermo Fisher Scientific Inc. (TMO) by 15,520 shares, valued at approximately $10.5 million. This information comes from the fund's latest Form 13F filing with the SEC.
Marathon's reported holdings in Thermo Fisher now stand at 60,648 shares, down from 76,168 shares, which is a 20.4% decrease. The total reported value of its position in the company is about $40.9 million.
TMO
Thermo Fisher Scientific Inc.
Where Thermo Fisher Fits in Marathon Asset Management's Portfolio
Thermo Fisher represents 3.25% of Marathon's overall portfolio, ranking as the 12th largest holding out of 76 total positions.
Other Institutional Activity in Thermo Fisher
In addition to Marathon, J. Safra Sarasin Holding also cut its position in Thermo Fisher, reducing its holdings by 29,845 shares, leaving it with 31,334 shares worth about $21.2 million. Meanwhile, Franklin Resources, Inc. increased its stake by 458,515 shares, bringing its total to 7,271,514 shares valued at approximately $4.98 billion.
Thermo Fisher Scientific Inc. Stock Down 0.4%
Thermo Fisher's stock closed at $684.89 on October 26, 2026, and was recently trading around $673.82 as of October 27, 2026. This recent trading level is about 1.6% below the closing price, suggesting a slight dip in investor sentiment following Marathon's cut.
Recent Earnings
Thermo Fisher Scientific reported trailing twelve-month revenue of approximately $47.4 billion, with a net margin of 14.9% and a return on equity of 13.4%. The next earnings report is scheduled for January 28, 2027.
Dividend
Thermo Fisher pays an annual dividend rate of $1.88 per share, which corresponds to a dividend yield of about 0.28% based on recent pricing.
Insider Buying and Selling at Thermo Fisher Scientific Inc.
Several insiders have sold shares recently. Lisa P. Britt, an officer, sold 11,440 shares at an average price of $613.12 on August 19, 2026, totaling about $7.0 million. CEO Marc N. Casper sold 20,000 shares on August 21, 2026, with a total value of approximately $12.6 million. Additionally, Gianluca Pettiti, the president, sold 4,133 shares at $614.38 on August 31, 2026, worth about $2.5 million.
Analysts Set New Price Targets
On October 22, 2026, several firms maintained their ratings on Thermo Fisher. Barclays kept an Overweight rating with a price target of $775, while RBC Capital maintained a Sector Perform rating with a target of $730. TD Cowen and Stifel both maintained Buy ratings with targets of $810 and $775, respectively. Citigroup also maintained a Buy rating with a target of $800.
About Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc. provides a wide range of scientific services and products, including life sciences solutions, analytical instruments, and laboratory products. The company serves various sectors, including healthcare and pharmaceuticals, making it a key player in the diagnostics and research industry.
Bottom Line
Investors should keep an eye on Thermo Fisher's upcoming earnings report on January 28, 2027, and watch for any further filings from Marathon Asset Management. The recent cuts by Marathon and J. Safra Sarasin may signal shifting strategies as the market evolves.
Related Filing Alerts
Source: Marathon Asset Management's 13F filing on $TMO (Oct 26, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Written by software, not financial advice. How we make alerts